ABSTRACT
We report the results of external quality assessment exercises in which 60 to 120
centers performed factor VIII (FVIII) inhibitor testing on a series of samples over
a 13-year period. Samples from seven different subjects were distributed for analysis
comprising the following: four different subjects with severe hemophilia A with antibodies
following replacement therapy, one subject with acquired hemophilia A and antibodies
to FVIII, one subject with normal FVIII and an easily detected lupus anticoagulant,
and one subject with mild hemophilia A and a difficult-to-detect lupus anticoagulant
but without antibodies to FVIII. In all of the surveys the results obtained in different
centers analyzing the same sample varied to an extent that would influence patient
management decisions. In the UK National External Quality Assessment Scheme surveys
reported here, there was considerable interlaboratory variation in the results of
FVIII inhibitor testing that did not improve over the survey period. The coefficient
of variation of results in different centers was between 33% and 106% in samples from
patients with severe congenital hemophilia A. In some cases, results were affected
by assay components. For one plasma, the mean FVIII inhibitor results in centers using
one source of normal plasma was 3.9 Bethesda unit (BU)/mL compared with a mean of
5.7 BU/mL in centers using a different normal plasma source (p = 0.04). Our data indicate that the detection of FVIII inhibitors is not the same
in different centers, and the degree of variability noted makes it likely that assay
variability has contributed to the lack of international consensus in relation to
the real incidence of FVIII inhibitors in different clinical settings. Improvements
in assay standardization are urgently needed.
KEYWORDS
FVIII inhibitor - quality assurance
REFERENCES
1
McMillan C W, Shapiro S S, Whitehurst D, Hoyer L W, Rao A V, Lazerson J.
The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national
cooperative study. II. Observations on the initial development of factor VIII:C inhibitors.
Blood.
1988;
71(2)
344-348
2
Ehrenforth S, Kreuz W, Scharrer I et al..
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.
Lancet.
1992;
339(8793)
594-598
3
Rasi V, Ikkala E.
Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome.
Br J Haematol.
1990;
76(3)
369-371
4
Addiego J, Kasper C, Abildgaard C et al..
Frequency of inhibitor development in haemophiliacs treated with low-purity factor
VIII.
Lancet.
1993;
342(8869)
462-464
5
Lusher J M, Arkin S, Abildgaard C F, Schwartz R S.
Recombinant factor VIII for the treatment of previously untreated patients with haemophilia
A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated
Patient Study Group.
N Engl J Med.
1993;
328
453-459
6
Kasper C, Aledort L, Counts R et al..
Letter: A more uniform measurement of factor VIII inhibitors.
Thromb Diath Haemorrh.
1975;
34(3)
869-872
7
Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E.
The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved
specificity and reliability.
Thromb Haemost.
1995;
73(2)
247-251
8
Giles A R, Verbruggen B, Rivard G E, Teitel J, Walker I. Association of Hemophilia
Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization
Committee of International Society on Thrombosis and Haemostasis .
A detailed comparison of the performance of the standard versus the Nijmegen modification
of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population
of Canada.
Thromb Haemost.
1998;
79(4)
872-875
9
Rubinger M, Lillicrap D, Rivard G E et al..
A prospective surveillance study of factor VIII inhibitor development in the Canadian
haemophilia A population following the switch to a recombinant factor VIII product
formulated with sucrose.
Haemophilia.
2008;
14
281-286
10
Peerschke E I, Castellone D D, Ledford-Kraemer M, Van Cott E M, Meijer P. NASCOLA
Proficiency Testing Committee .
Laboratory assessment of factor VIII inhibitor titer: the North American Specialized
Coagulation Laboratory Association experience.
Am J Clin Pathol.
2009;
131(4)
552-558
11
Parker E T, Craddock H N, Barrow R T, Lollar P.
Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and
Hyate:C in hemophilia A mice presensitized to human factor VIII.
J Thromb Haemost.
2004;
2(4)
605-611
12
Kitchen S, Walker I D, Woods T A, Preston F E.
Thromboplastin related differences in the determination of international normalised
ratio: a cause for concern? Steering Committee of the UK National External Quality
Assessment Scheme for Blood Coagulation.
Thromb Haemost.
1994;
72
426-429
13
Favaloro E J, Bonar R, Duncan E RCPA QAP in Haematology Haemostasis Committee et al.
Identification of factor inhibitors by diagnostic haemostasis laboratories: a large
multi-centre evaluation.
Thromb Haemost.
2006;
96(1)
73-78
14
Hay C R, Brown S, Collins P W, Keeling D M, Liesner R.
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the
United Kingdom Haemophilia Centre Doctors Organisation.
Br J Haematol.
2006;
133
591-605
15
Gringeri A, Mannucci P M. Italian Association of Haemophilia Centres .
Italian guidelines for the diagnosis and treatment of patients with haemophilia and
inhibitors.
Haemophilia.
2005;
11(6)
611-619
16
Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novákovà I.
The type of factor VIII deficient plasma used influences the performance of the Nijmegen
modification of the Bethesda assay for factor VIII inhibitors.
Thromb Haemost.
2001;
86(6)
1435-1439
17
Kazmi M A, Pickering W, Smith M P, Holland L J, Savidge G F.
Acquired haemophilia A: errors in the diagnosis.
Blood Coagul Fibrinolysis.
1998;
9(7)
623-628
18 Kitchen S, McCraw A. Diagnosis of Haemophilia and Other Bleeding Disorders. Montreal,
Quebec, Canada; The World Federation of Hemophilia; 2001 Available at: http://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Lab_manual_web.pdf Accessed December 7, 2009
19
Biggs R, Austen D E, Denson K W, Rizza C R, Borrett R.
The mode of action of antibodies which destroy factor VIII. I. Antibodies which have
second-order concentration graphs.
Br J Haematol.
1972;
23
125-135
20
Biggs R, Austen D E, Denson K W, Borrett R, Rizza C R.
The mode of action of antibodies which destroy factor VIII. II. Antibodies which give
complex concentration graphs.
Br J Haematol.
1972;
23
137-155
Steve KitchenPh.D.
UK National External Quality Assessment Scheme (Blood Coagulation)
Rutledge Mews, 3 Southbourne Rd., Sheffield, S10 2QN, United Kingdom
Email: steve.kitchen@sth.nhs.uk